AME vs REPL · P/E 30, rev $6.94B vs $825.7M cap
Ametek Inc (AME) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Ametek Inc (AME) is a specialty industrial machinery company listed on US.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported AME revenue for 2024-12-31 was $6.94B. Net income was $1.38B. Revenue was up 5.2% from 2023-12-31 to 2024-12-31. AME currently screens at market cap $42.11B and trailing P/E 29.9.
REPL does not have a complete income-statement cache yet.
AME currently screens at market cap $42.11B and trailing P/E 29.9. REPL currently screens at market cap $825.7M.
Not investment advice. Open the AME and REPL stock pages for the full models.
Not investment advice.